产品说明书

Iptacopan HCl

Print
Chemical Structure| 1646321-63-2 同义名 : LNP023 hydrochloride;Iptacopan Hydrochloride;LNP023 HCl
CAS号 : 1646321-63-2
货号 : A1362839
分子式 : C25H31ClN2O4
纯度 : 98%
分子量 : 458.978
MDL号 : N/A
存储条件：

粉末 Inert atmosphere,2-8°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 250 mg/mL(544.69 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H2O: 50 mg/mL(108.94 mM)，配合低频超声，并水浴加热至45℃助溶
动物实验配方：
生物活性
描述 LNP023 hydrochloride is an orally bioavailable, highly potent, and highly selective inhibitor of factor B. LNP023 exhibits direct, reversible, and high-affinity binding to human factor B, with a KD of 7.9 nM.
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.18mL

0.44mL

0.22mL

10.89mL

2.18mL

1.09mL

21.79mL

4.36mL

2.18mL
参考文献

[1]Dimitrios C Mastellos, et al. Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria. Semin Hematol. 2018 Jul;55(3):167-175.

[2]Anna Schubart, et al. Small-molecule Factor B Inhibitor for the Treatment of Complement-Mediated Diseases. Proc Natl Acad Sci U S A. 2019 Apr 16;116(16):7926-7931.

[3]Nello Mainolfi, et al. Discovery of 4-((2 S,4 S)-4-Ethoxy-1-((5-methoxy-7-methyl-1 H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases. J Med Chem. 2020 Jun 11;63(11):5697-5722.